Bailard’s Spero Therapeutics SPRO Stock Holding History

Bailard’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-60,900	Closed	-$105K	–	808
2024 Q1	$105K	Buy	+60,900	New	+$95.5K	﹤0.01%	724

Other funds holding SPRO

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bailard's SPRO Position: Q2 2024 in Review

Bailard sold out of Spero Therapeutics (SPRO) in Q2 2024, closing a stake of 60,900 shares — an estimated $105K sold.

Bailard first reported a position in SPRO in Q1 2024 and held it in 1 quarter. The position peaked at $105K in Q1 2024. 48 funds tracked by Wall St. Rank hold SPRO as of Q2 2024.

Bailard reported no remaining Spero Therapeutics position as of Q2 2024 after selling out during the quarter.
Bailard sold 60,900 Spero Therapeutics shares in Q2 2024, an estimated $105K.
Bailard first reported a position in Spero Therapeutics in Q1 2024 and held it in 1 quarter.
Bailard's Spero Therapeutics position peaked at $105K in Q1 2024.
48 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2024.

Based on Bailard's 13F filing for Q2 2024, filed 25 Jul 2024.